Skip to content
Preprint · OA via OpenAlex

α‐synuclein genetic variability: A biomarker for dementia in Parkinson disease

Ilaria Guella, Daniel M. Evans, Chelsea Szu‐Tu, Ekaterina Nosova, Stephanie Bortnick, SNCA Cognition Study Group, Jennifer G. Goldman, John C. Dalrymple‐Alford, Gert J. Geurtsen, Irene Litvan, Owen A. Ross, Lefkos T. Middleton, Laura Parkkinen, Matthew James Farrer

Annals of Neurology · 2016 · ▲ 94 citations

Abstract

OBJECTIVE: The relationship between Parkinson disease (PD), PD with dementia (PDD), and dementia with Lewy bodies (DLB) has long been debated. Although PD is primarily considered a motor disorder, cognitive impairment is often present at diagnosis, and only ∼20% of patients remain cognitively intact in the long term. Alpha-synuclein (SNCA) was first implicated in the pathogenesis of the disease when point mutations and locus multiplications were identified in familial parkinsonism with dementia. In worldwide populations, SNCA genetic variability remains the most reproducible risk factor for idiopathic PD. However, few investigators have looked at SNCA variability in terms of cognitive outcomes. METHODS: We have used targeted high-throughput sequencing to characterize the 135kb SNCA locus in a large multinational cohort of patients with PD, PDD, and DLB and healthy controls. RESULTS: An analysis of 43 tagging single nucleotide polymorphisms across the SNCA locus shows 2 distinct association profiles for symptoms of parkinsonism and/or dementia, respectively, toward the 3' or the 5' of the SNCA gene. In addition, we define a specific haplotype in intron 4 that is directly associated with PDD. The PDD risk haplotype has been interrogated at single nucleotide resolution and is uniquely tagged by an expanded TTTCn repeat. INTERPRETATION: Our data show that PD, PDD, and DLB, rather than a disease continuum, have distinct genetic etiologies albeit within one genomic locus. Such results may serve as prognostic biomarkers to these disorders, to inform physicians and patients, and to assist in the design and stratification of clinical trials aimed at disease modification. Ann Neurol 2016;79:991-999.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1002/ana.24664
Canonical
link ↗
Fetched
2026-10-29 MST

Cite this

APA
Guella, I., Evans, D.M., Szu‐Tu, C., Nosova, E., Bortnick, S., Group, S.C.S., Goldman, J.G., Dalrymple‐Alford, J.C., Geurtsen, G.J., Litvan, I., Ross, O.A., Middleton, L.T., Parkkinen, L., &amp; Farrer, M.J. (2016). α‐synuclein genetic variability: A biomarker for dementia in Parkinson disease. <em>Annals of Neurology</em>. https://doi.org/10.1002/ana.24664
Vancouver
Guella I, Evans DM, Szu‐Tu C, Nosova E, Bortnick S, Group SCS, et al. α‐synuclein genetic variability: A biomarker for dementia in Parkinson disease. Annals of Neurology. 2016. doi:10.1002/ana.24664.
BibTeX
@unpublished{ilaria2016synucl, title = {α‐synuclein genetic variability: A biomarker for dementia in Parkinson disease}, author = {Ilaria Guella and Daniel M. Evans and Chelsea Szu‐Tu and Ekaterina Nosova and Stephanie Bortnick and SNCA Cognition Study Group and Jennifer G. Goldman and John C. Dalrymple‐Alford and Gert J. Geurtsen and Irene Litvan and Owen A. Ross and Lefkos T. Middleton and Laura Parkkinen and Matthew James Farrer}, journal = {Annals of Neurology}, year = {2016}, doi = {10.1002/ana.24664}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings